Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
4.620
+0.170 (3.82%)
Jan 17, 2025, 4:00 PM EST - Market closed
Camp4 Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 |
Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Revenue | - | 0.35 | - |
Cost of Revenue | 37.93 | 39.06 | 34.1 |
Gross Profit | -37.93 | -38.71 | -34.1 |
Selling, General & Admin | 13.05 | 11.61 | 10.23 |
Research & Development | 1.56 | 1.56 | 0.68 |
Operating Expenses | 14.6 | 13.17 | 10.91 |
Operating Income | -52.53 | -51.88 | -45 |
Interest & Investment Income | 1.29 | 2.81 | 0.9 |
Other Non Operating Income (Expenses) | -0.26 | -0.22 | -0.1 |
Pretax Income | -51.5 | -49.29 | -44.19 |
Net Income | -51.5 | -49.29 | -44.19 |
Net Income to Common | -51.5 | -49.29 | -44.19 |
Shares Outstanding (Basic) | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 0 | 0 | 0 |
Shares Change (YoY) | 55.25% | 26.47% | - |
EPS (Basic) | -106.23 | -124.79 | -141.51 |
EPS (Diluted) | -106.23 | -124.79 | -141.51 |
Free Cash Flow | -46.48 | -44.83 | -42.57 |
Free Cash Flow Per Share | -95.86 | -113.51 | -136.31 |
Operating Margin | - | -14822.57% | - |
Profit Margin | - | -14083.14% | - |
Free Cash Flow Margin | - | -12809.43% | - |
EBITDA | -50.82 | -50.2 | -44.12 |
D&A For EBITDA | 1.71 | 1.68 | 0.88 |
EBIT | -52.53 | -51.88 | -45 |
Source: S&P Capital IQ. Standard template.
Financial Sources.